Bayer AG (BAYN) Rating Reiterated by DZ Bank AG
Bayer AG (FRA:BAYN)‘s stock had its “buy” rating reiterated by equities research analysts at DZ Bank AG in a research report issued on Tuesday.
A number of other research analysts also recently issued reports on BAYN. Barclays PLC set a €105.00 ($122.09) price target on Bayer AG and gave the company a “sell” rating in a report on Monday, November 6th. UBS AG set a €125.00 ($145.35) target price on Bayer AG and gave the company a “buy” rating in a report on Monday, November 6th. Jefferies Group LLC set a €137.00 ($159.30) price objective on Bayer AG and gave the stock a “buy” rating in a research note on Tuesday. J P Morgan Chase & Co set a €125.00 ($145.35) price objective on Bayer AG and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, HSBC Holdings plc set a €105.00 ($122.09) target price on Bayer AG and gave the stock a “neutral” rating in a research report on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company’s stock. Bayer AG presently has a consensus rating of “Buy” and an average price target of €122.33 ($142.25).
Bayer AG (FRA BAYN) opened at €109.00 ($126.74) on Tuesday. Bayer AG has a 1-year low of €86.06 ($100.07) and a 1-year high of €123.82 ($143.98).
COPYRIGHT VIOLATION NOTICE: “Bayer AG (BAYN) Rating Reiterated by DZ Bank AG” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/11/14/bayer-ag-bayn-rating-reiterated-by-dz-bank-ag.html.
About Bayer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.